Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-21
2011-06-21
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S375000, C514S443000, C548S218000, C548S302100
Reexamination Certificate
active
07964598
ABSTRACT:
The present invention provides compounds that inhibit apoE4 domain interaction; and compositions, including pharmaceutical compositions, comprising the compounds. The present invention provides methods of treating apoE4-related disorders. The methods generally involve administering to an individual in need thereof a therapeutically effective amount of an apoE4 domain interaction inhibitor.
REFERENCES:
patent: 4582779 (1986-04-01), Kubota et al.
patent: 4983586 (1991-01-01), Bodor
patent: 5002935 (1991-03-01), Bodor
patent: 5017566 (1991-05-01), Bodor
patent: 5153179 (1992-10-01), Eibl
patent: 2002/0009439 (2002-01-01), Mahley et al.
patent: 2004/0223916 (2004-11-01), Burt et al.
patent: 1079075 (1967-08-01), None
patent: 08-292183 (1996-11-01), None
patent: 11-242026 (1999-09-01), None
patent: WO 94/13798 (1994-06-01), None
patent: WO 95/06456 (1995-03-01), None
patent: WO 95/06470 (1995-03-01), None
patent: WO 97/14437 (1997-04-01), None
“Sigma Catalog” 2000, Sigma Chemical Company, p. 145, col. 1. XP002278833.
Elokdah et al. Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties. (2004) J. Med.Chem., 47, 681-695.
Alberts, Mark J., et al., (1995) “ApoE Genotype and Survival from Intracerebral Haemorrhage”,The Lancet346:575.
Beffert, U., et al., (1995) “Apolipoprotein E Uptake is Increased in the Presence of Beta Amyloid Peptides and Reduced by Blockade of the Low Density Lipoprotein Receptor”,Society for Nueroscience21:6.
Baba et al. (1991) “Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats.”J. Cereb. Blood Flow Metab., vol. 11:638-643.
Battey et al. (1994) “The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor.”J. Biol. Chem., vol. 269:23268-23273.
Bellosta et al. (1995) “Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects of neurite outgrowth.”J. Biol. Chem., vol. 270:27063-27071.
Bickel et al. (1993) “Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.”Proc. Natl. Acad. Sci. USA, vol. 90:2618-2622.
Bilheimer et al. (1972) “The metabolism of very low density lipoproteins I. Preliminary in vitro and in vivo observations.”Biochem. Biophys. Acta., vol. 260:212-221.
Borth (1992) “α2-macroglobulin, a multifunctional binding protein with targeting characteristics.”Faseb J., vol. 6:3345-3353.
Bottenstein et al. (1980) “Fibronectin and polylysine requirement for proliferation of neuroblastoma cells in defined medium.”Exp. Cell Res., vol. 129:361-366.
Boyles et al. (1985) “Apoliprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.”J. Clin. Invest., vol. 76:1501-1513.
Boyles et al. (1989) “A role for apolipoprotein E, apoliprotein A-1, and low density lipoprotein receptors in cholesterol transport.”J. Clin. Invest., vol. 83:1015-1031.
Chappell et al. (1993) “Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/α2-macroglobulin recentor in vitro ”J Biol. Chem., vol. 268:14168-14175.
Chen et al. (1988) “Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA.”Bio Techniques, vol. 6:632-638.
Corder et al. (1993) “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.”Science, vol. 261:921-923.
Crowther (1993) “Tau protein and paired helical filaments of Alzheimer's disease.”Curr. Opin. Struct. Biol., vol. 3:202-206.
Dong et al. (1994) “Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.”J. Biol. Chem., vol. 269:22358-22365.
Dong et al. (1995) “Apolipdprotein E4 preference for very low density lipoproteins results from domain interaction mediated by glutamic acid-255 and arginine-61.”Circulation, vol. 92:I-427-I-428.
Elshourbagy et al. (1985) “Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets ”Proc Natl. Acad. Sci. USA.vol. 82:203-207.
Feskens et al. (1994) “Apolipoprotein e4 allele and cognitive decline in elderly men.”BMJ, vol. 309:1202-1206.
Forss-Petter et al. (1990) “Transgenic mice expressing β-galactosidase in mature nerons under neuron-specific enolase promoter control.”Neuron, vol. 5:187-197.
Gennuso et al. (1993) “Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system iposomal uptake.”Cancer Invest., vol. 11:118-128.
Godyna et al. (1995) “Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1.”J. Cell. Biol., vol. 129:1403-1410.
Goldstein et al. (1983) “Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.”Met. Enzymol., vol. 98:241-260.
Handelmann et al. (1992) “Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on the extension of neuritis by rabbit dorsal root ganglion neurons in vitro.”J. Lipid Res., vol. 33:1677-1688.
Helkala et al. (1995) “The association of apolipoprotein E polymorphism with memory: a population based study.”Neurosci. Letts., vol. 191:141-144.
Hoeg et al. (1987) “3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholsterolemia.”JAMA, vol. 258:3532-3536.
Holtzman et al. (1995) “LRP mediates apolipoprotein E-dependent neurite outgrowth in a CNS-derived neuronal cell line.”Soc. Neurosci., vol. 21:1009.
Humphries et al. (1989) “Decreasing sulfation of proteoglycans produced by cultured cells.”Met. Enzymol., vol. 179:428-434.
Hyman et al. “α2-macroglobulin receptor/low density lipoprotein receptor-related protein.”Annals new York Academy of Sciences, pp. 88-95, (1994).
Ignatius et al. (1986) “Expression of apolipoprotein E during nerve degeneration and regeneration.”Proc. Natl. Acad. Sci. USA, vol. 83:1125-1129.
Ignatius et al. (1987) “Lipoprotein uptake by neuronal growth cones in vitro.”Science, vol. 236:959-962.
Innerarity et al. (1979) “Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts.”J. Biol. Chem., vol. 254:4186-4190.
Innerarity et al. (1983) “The receptor-binding domain of human apolipoprotein E.”J. Biol. Chem., vol. 258:12341-12347.
Jackowski, Andres, (1995) “Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer”,British Journal of Neurosurgery, 9:303-317.
Ji et al. (1994) “Secretion-capture role for aoplipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.”J. Biol. Chem., vol. 269:2764-2772.
Ji et al. (1994) “Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein.”Arterioscler. Thromb., vol. 14:2025-2032.
Ji et al. (1994) “Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture.”J. Biol. Chem., vol. 269:13429-13436.
Ji et al. (1993) “Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells.”J. Biol. Chem., vol. 268:10160-10167.
Kostis et al. (1994) “Central nervous system effects of HMG CoA reductase inhibitors: Lovastatin and
Huang Yadong
Mahley Robert W.
Weisgraber Karl H.
Borden Paula A.
Bozicevic Field & Francis LLP
Carter Kendra D
Padmanabhan Sreeni
The J. David Gladstone Institutes
LandOfFree
ApoE4 domain interaction inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ApoE4 domain interaction inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ApoE4 domain interaction inhibitors and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712133